Meeting Banner
Abstract #4149

DCE-MRI at 3T in Patients with Advanced Ovarian Cancer Undergoing Neo-Adjuvant Chemotherapy

Andrew Nicholas Priest1, Andrew B. Gill2, Masako Y. Kataoka1, Ilse Joubert1, Mary A. McLean3, Martin J. Graves1, John R. Griffiths3, Robin Crawford4, Helena Earl5, James Brenton3,5, David J. Lomas1, Evis Sala1

1Radiology, Addenbrookes Hospital and University of Cambridge, Cambridge, UK; 2Medical Physics, Addenbrookes Hospital, Cambridge, UK; 3Cambridge Research Institute, Cancer Research UK, Cambridge, UK; 4Obstetrics & Gynaecology,, Addenbrookes Hospital, Cambridge, UK; 5Oncology, Addenbrookes Hospital, Cambridge, UK

Ovarian cancer is a genetically heterogeneous disease with a poor prognosis, and treatment individualisation could be aided by an ability to predict treatment outcome e.g. through measurements reflecting tumour blood supply. This study reports measurements of dynamic contrast enhanced MRI before and after neo-adjuvant chemotherapy, in primary ovarian tumour, omental cake and peritoneal deposits. A reduction in kep following treatment was found for ovarian and peritoneal tumours, with no change in the omental cake. There were no significant changes in Ktrans or area under the curve, possibly due to the small number of patients (14) studied so far.